Gene therapies hold great promise for one-time treatments that alleviate or cure certain genetic conditions. Recombinant adenoassociated viral (AAV) and lentiviral vectors have emerged as leading gene delivery methods for in vivo and ex vivo gene therapies, respectively. With more than 500 gene therapy clinical trials underway, the industry needs scalable, cost-efficient viral vector manufacturing.
To address those needs, Corning developed the Ascent fixed-bed bioreactor system for scalable, high-density, adherent cell culture, including high-yield viral vector manufacturing. The Ascent fixed-bed bioreactor system includes a specially treated and packed polymer mesh that enables uniform low-shear fluid flow through the bioreactor bed. The system also provides homogenous cell attachment and growth, >90% transfection efficiency, and a significantly higher AAV vector yield/m2 than other fixed-bed reactors. Furthermore, the ability to harvest viable cells from the Ascent system enables its use in seed train and other applications for which the harvest of viable cells is needed.
Fill out the form below to read the complete technology review now.